Ligand: Q4 Earnings Snapshot [Yahoo! Finance]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Yahoo! Finance
JUPITER, Fla. (AP) — JUPITER, Fla. (AP) — Ligand Pharmaceuticals Inc. (LGND) on Thursday reported fourth-quarter earnings of $44.8 million. On a per-share basis, the Jupiter, Florida-based company said it had net income of $2.12. Earnings, adjusted for non-recurring gains, were $2.02 per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.46 per share. The drugmaker posted revenue of $59.7 million in the period, which also beat Street forecasts. Four analysts surveyed by Zacks expected $58.2 million. For the year, the company reported profit of $124.5 million, or $6.13 per share. Revenue was reported as $268.1 million. Ligand expects full-year earnings in the range of $8 to $9 per share, with revenue in the range of $245 million to $285 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Resear
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand Pharmaceuticals (LGND) had its price target raised by Oppenheimer Holdings, Inc. from $275.00 to $277.00. They now have an "outperform" rating on the stock.MarketBeat
- Ligand Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Ligand Pharma (LGND) Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Ligand Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Ligand Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
LGND
Earnings
- 2/26/26 - Beat
LGND
Sec Filings
- 2/26/26 - Form 8-K
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- LGND's page on the SEC website